Assignee
TAKEDA PHARMACEUTICALS CO
JP·551 granted patents·305 pending applications·1,253 citations·filing 2001–2025
Top patents by PatentIndex Score
856 records- 0198US11731983B2Production method of thienopyrimidine derivativeTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Aug 22, 2023·7 cites·10 claims
- 0298US10544160B2Production method of thienopyrimidine derivativeTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Jan 28, 2020·19 cites·3 claims
- 0398US10464945B2Crystalline forms of thienopyrimidine derivativeTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Nov 5, 2019·21 cites·8 claims
- 0498US10150778B2Production method of thienopyrimidine derivativeTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Dec 11, 2018·24 cites·2 claims
- 0597US11795178B2Compositions of thienopyrimidine derivativesTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Oct 24, 2023·7 cites·87 claims
- 0697US11053257B2Production method of thienopyrimidine derivativeTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Jul 6, 2021·14 cites·1 claims
- 0797US10428023B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Oct 1, 2019·22 cites·1 claims
- 0897US10287305B2Substituted piperidine compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted May 14, 2019·19 cites·3 claims
- 0996US12325714B2Compositions of thienopyrimidine derivativesTAKEDA PHARMACEUTICALS CO·Filed 2024·Granted Jun 10, 2025·1 cites·30 claims
- 1096US12180224B2Thienopyrimidine derivatives and production methods thereofTAKEDA PHARMACEUTICALS CO·Filed 2023·Granted Dec 31, 2024·4 cites·22 claims
- 1196US11505620B2Methods of detecting plasma kallikreinTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Nov 22, 2022·6 cites·20 claims
- 1296US10898737B2Substituted piperidine compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Jan 26, 2021·10 cites·1 claims
- 1396US10584097B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Mar 10, 2020·14 cites·1 claims
- 1496US10508083B2Substituted piperidine compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Dec 17, 2019·15 cites·1 claims
- 1596US9758528B2Production method of thienopyrimidine derivativeTAKEDA PHARMACEUTICALS CO·Filed 2013·Granted Sep 12, 2017·29 cites·5 claims
- 1695US12447169B2Maribavir isomers, compositions, methods of making and methods of usingTAKEDA PHARMACEUTICALS CO·Filed 2024·Granted Oct 21, 2025·2 cites·8 claims
- 1795US12110343B2Anti-plasma kallikrein antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Oct 8, 2024·4 cites·10 claims
- 1895US12084515B2Compositions and methods for treatment of diabetic macular edemaTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Sep 10, 2024·4 cites·10 claims
- 1995US12053526B2Methods for treatment using anti-alpha4beta7 antibodyTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Aug 6, 2024·5 cites·34 claims
- 2095US11684632B2Maribavir isomers, compositions, methods of making and methods of usingTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jun 27, 2023·7 cites·16 claims
- 2195US11370803B2Heteroaryl plasma kallikrein inhibitorsTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jun 28, 2022·5 cites·17 claims
- 2295US11084884B2Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedemaTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Aug 10, 2021·23 cites·17 claims
- 2395US11028048B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jun 8, 2021·8 cites·9 claims
- 2495US9878989B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jan 30, 2018·7 cites·2 claims
- 2595US9676869B2Conjugated anti-CD38 antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Jun 13, 2017·12 cites·20 claims
- 2694US12061206B2Diagnosis and treatment of autoimmune diseasesTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Aug 13, 2024·3 cites·13 claims
- 2794US11787796B2Plasma Kallikrein inhibitors and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Oct 17, 2023·4 cites·20 claims
- 2894US11744892B2Constrained conditionally activated binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Sep 5, 2023·2 cites·1 claims
- 2994US11744893B2Constrained conditionally activated binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Sep 5, 2023·2 cites·1 claims
- 3094US11440883B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Sep 13, 2022·3 cites·1 claims
- 3194US11191837B2Recombinant VWF formulationsTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Dec 7, 2021·9 cites·12 claims
- 3294US10494444B2Anti-CD38 antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Dec 3, 2019·8 cites·10 claims
- 3394US10336833B2Conjugated anti-CD38 antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Jul 2, 2019·9 cites·30 claims
- 3494US9518042B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Dec 13, 2016·8 cites·2 claims
- 3594US9499516B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Nov 22, 2016·8 cites·2 claims
- 3694US2025099559A1Stabilized liquid and lyophilized adamts13 formulationsTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 3793USD1012092SDisplay screen with a transitional graphical user interfaceTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jan 23, 2024·39 cites·1 claims
- 3893US11725024B2Antibody drug conjugatesTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Aug 15, 2023·3 cites·14 claims
- 3993US11406710B2Constrained conditionally activated binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Aug 9, 2022·8 cites·13 claims
- 4093US11352356B2Inhibitors of plasma kallikrein and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jun 7, 2022·4 cites·29 claims
- 4193US11340237B2Metabolite biomarkers for diseases associated with the contact activation systemTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted May 24, 2022·7 cites·26 claims
- 4293US11292766B2Substituted piperidine compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Apr 5, 2022·6 cites·10 claims
- 4393US11230545B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Jan 25, 2022·2 cites·4 claims
- 4493US11130777B2Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1-beta-L-ribofuranosyl)-1H-benzimidazoleTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Sep 28, 2021·8 cites·20 claims
- 4593US10610520B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Apr 7, 2020·9 cites·12 claims
- 4693US10323026B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Jun 18, 2019·20 cites·10 claims
- 4793US10087150B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Oct 2, 2018·5 cites·2 claims
- 4893US9718814B2Cyclopropanamine compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Aug 1, 2017·5 cites·2 claims
- 4993US9714241B2Cyclopropanamine compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jul 25, 2017·5 cites·2 claims
- 5093US9487511B2Cyclopropanamine compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Nov 8, 2016·5 cites·2 claims
Showing the top 50 of 856 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when TAKEDA PHARMACEUTICALS CO files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →